Katherine Van Loon

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405
    Katherine Van Loon
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 12:95-102. 2013
  2. ncbi request reprint Counterpoint: Adjuvant therapy in stage II colon cancer: pain not justified by the gain
    Katherine Van Loon
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    J Natl Compr Canc Netw 10:1379-86. 2012
  3. doi request reprint Adjuvant treatment of colon cancer: what is next?
    Katherine Van Loon
    Division of Hematology Oncology, Department of Medicine, University of California San Francisco, San Francisco, California 94115, USA
    Curr Opin Oncol 23:403-9. 2011

Detail Information

Publications3

  1. pmc Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405
    Katherine Van Loon
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 12:95-102. 2013
    ..We describe the prevalence of a wide-range of health-related dietary patterns and lifestyle behaviors among colorectal cancer patients with stage III and metastatic disease and report notable similarities in these 2 cohorts...
  2. ncbi request reprint Counterpoint: Adjuvant therapy in stage II colon cancer: pain not justified by the gain
    Katherine Van Loon
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    J Natl Compr Canc Netw 10:1379-86. 2012
    ..Given what is now known, the viewpoint is that the aggregate data do not support adjuvant therapy for patients with normal-risk stage II colon cancer...
  3. doi request reprint Adjuvant treatment of colon cancer: what is next?
    Katherine Van Loon
    Division of Hematology Oncology, Department of Medicine, University of California San Francisco, San Francisco, California 94115, USA
    Curr Opin Oncol 23:403-9. 2011
    ..In addition, we examine how results of these trials have shaped our knowledge and outline directions for future research...